Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer.
暂无分享,去创建一个
J. Mackey | M. Smylie | H. Au | K. Tonkin | D. Soulières | A. Joy | A. Scarfe | Stephanie W. Smith | S. Koski | D. Bodnar | Stephanie Smith
[1] V. Valero,et al. Docetaxel secretion in tears: association with lacrimal drainage obstruction. , 2002, Archives of ophthalmology.
[2] David Miles,et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] G. Hortobagyi,et al. Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer. , 2002, Ophthalmology.
[4] C. Shapiro,et al. Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] G. Hortobagyi,et al. Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] H Sommer,et al. Weekly docetaxel (Taxotere) in patients with metastatic breast cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] J. Hainsworth,et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] K. Myers,et al. Does This Patient Have Clubbing , 2001 .
[9] J. Manola,et al. Docetaxel administered on a weekly basis for metastatic breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] A. Buzdar,et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] J. Hainsworth,et al. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] H. Ishitsuka,et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[13] G. Hortobagyi. Chemotherapy of breast cancer: a historical perspective. , 1997, Seminars in oncology.
[14] M. Aapro,et al. Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer. , 1997, Oncology.
[15] S. Chan. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy. , 1997, Oncology.
[16] Neal Devitt,et al. The rational clinical examination. , 1992, JAMA.
[17] Terry L. Smith,et al. Results and long term follow‐up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin‐containing chemotherapy , 1999, Cancer.